MENU
+Compare
NBIX
Stock ticker: NASDAQ
AS OF
Oct 14 closing price
Price
$137.23
Change
-$0.12 (-0.09%)
Capitalization
13.61B

NBIX Neurocrine Biosciences Forecast, Technical & Fundamental Analysis

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States... Show more

Industry: #Biotechnology
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NBIX with price predictions
Oct 14, 2025

NBIX in downward trend: 10-day moving average broke below 50-day moving average on October 14, 2025

The 10-day moving average for NBIX crossed bearishly below the 50-day moving average on October 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 29, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on September 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

NBIX moved below its 50-day moving average on October 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 282 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.051) is normal, around the industry mean (17.643). P/E Ratio (40.586) is within average values for comparable stocks, (72.868). Projected Growth (PEG Ratio) (0.360) is also within normal values, averaging (2.089). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (5.612) is also within normal values, averaging (48.567).

View a ticker or compare two or three
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NBIX is expected to report earnings to fall 4.24% to $1.58 per share on October 28

Neurocrine Biosciences NBIX Stock Earnings Reports
Q3'25
Est.
$1.58
Q2'25
Beat
by $0.69
Q1'25
Missed
by $0.07
Q4'24
Beat
by $0.12
Q3'24
Beat
by $0.29
The last earnings report on July 30 showed earnings per share of $1.65, beating the estimate of 95 cents. With 598.54K shares outstanding, the current market capitalization sits at 13.61B.
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12780 El Camino Real
Phone
+1 858 617-7600
Employees
1400
Web
https://www.neurocrine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SOFX41.892.01
+5.03%
Defiance Daily Target 2X Long SOFI ETF
NPFI26.300.01
+0.04%
Nuveen Preferred and Income ETF
JPI20.68N/A
N/A
Nuveen Preferred Securities & Income Opportunities Fund
ARVR50.47N/A
N/A
First Trust Indxx Metaverse ETF
FENY23.99-0.04
-0.17%
Fidelity MSCI Energy ETF

NBIX and Stocks

Correlation & Price change

A.I.dvisor tells us that NBIX and ELAN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-0.12%
ELAN - NBIX
33%
Poorly correlated
+0.90%
LFCR - NBIX
32%
Poorly correlated
-0.91%
CGC - NBIX
30%
Poorly correlated
-0.73%
AMRX - NBIX
30%
Poorly correlated
-0.31%
AQST - NBIX
29%
Poorly correlated
+3.30%
More

Groups containing NBIX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-0.12%
Pharmaceuticals: Generic
industry (221 stocks)
48%
Loosely correlated
+1.43%